

Sean D Pokorney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4476210/publications.pdf>

Version: 2024-02-01

89
papers

1,643
citations

394421

19
h-index

330143

37
g-index

90
all docs

90
docs citations

90
times ranked

2945
citing authors

#	ARTICLE	IF	CITATIONS
1	Atrial branch coronary artery stenosis as a mechanism for atrial fibrillation. <i>Heart Rhythm</i> , 2022, 19, 1237-1244.	0.7	8
2	Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants. <i>JAMA Network Open</i> , 2022, 5, e2214321.	5.9	4
3	Evidence Builds for Catheter Ablation for Atrial Fibrillation and Heart Failure. <i>Circulation</i> , 2022, 145, 1705-1707.	1.6	2
4	Implantable Cardioverter Defibrillator Utilization and Mortality Among Patients ≥65 Years of Age With a Low Ejection Fraction After Coronary Revascularization. <i>American Journal of Cardiology</i> , 2021, 138, 26-32.	1.6	6
5	Treatment of atrial fibrillation: is it as easy as A-B-C?. <i>Europace</i> , 2021, 23, 161-162.	1.7	1
6	Trends in health care resource use and expenditures in patients with newly diagnosed paroxysmal supraventricular tachycardia in the United States. <i>American Heart Journal</i> , 2021, 233, 132-140.	2.7	5
7	AORTIC VALVE ENDOCARDITIS AS A COMPLICATION OF TOCILIZUMAB TREATMENT IN COVID 19 PATIENT. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3002.	2.8	1
8	Prevalence and incidence of patients with paroxysmal supraventricular tachycardia in the United States. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 2199-2206.	1.7	14
9	Electrical storm in patients with left ventricular assist devices: Risk factors, incidence, and impact on survival. <i>Heart Rhythm</i> , 2021, 18, 1263-1271.	0.7	10
10	Comparative outcomes of Riata and Fidelis lead management strategies: Results from the NCDR-ICD Registry. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 1897-1906.	1.2	3
11	Hands on: How to approach patients undergoing lead extraction. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1801-1808.	1.7	3
12	Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. <i>American Heart Journal</i> , 2020, 220, 145-154.	2.7	3
13	Healthcare Resource Use and Expenditures in Patients Newly Diagnosed With Paroxysmal Supraventricular Tachycardia. <i>American Journal of Cardiology</i> , 2020, 125, 215-221.	1.6	9
14	Cardiovascular Implantable Electronic Device Surgery Following Left Ventricular Assist Device Implantation. <i>JACC: Clinical Electrophysiology</i> , 2020, 6, 1131-1139.	3.2	5
15	VVI pacing with normal QRS duration and ventricular function: MOST trial findings relevant to leadless pacemakers. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 1461-1466.	1.2	1
16	Underuse of oral anticoagulants in privately insured patients with atrial fibrillation: A population being targeted by the Implementation of a randomized controlled trial to improve treatment with oral Anticoagulants in patients with Atrial Fibrillation (IMPACT-AFib). <i>American Heart Journal</i> , 2020, 229, 110-117.	2.7	15
17	Disparities in the Management of Newly Diagnosed Paroxysmal Supraventricular Tachycardia for Women Versus Men in the United States. <i>Journal of the American Heart Association</i> , 2020, 9, e015910.	3.7	7
18	Catheter ablation of atrial fibrillation in patients with diabetes mellitus. <i>Heart Rhythm</i> O2, 2020, 1, 180-188.	1.7	11

#	ARTICLE	IF	CITATIONS
19	Warfarin for Atrial Fibrillation Stroke Prophylaxis in Advanced Kidney Disease. JACC: Clinical Electrophysiology, 2020, 6, 1669-1671.	3.2	1
20	Shared decision-making in atrial fibrillation: patient-reported involvement in treatment decisions. European Heart Journal Quality of Care & Clinical Outcomes, 2020, 6, 263-272.	4.0	16
21	Catheter ablation of atrial fibrillation in cardiac amyloidosis. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 913-921.	1.2	14
22	Lead Extraction for Cardiovascular Implantable Electronic Device Infection in Patients With Left Ventricular Assist Devices. JACC: Clinical Electrophysiology, 2020, 6, 672-680.	3.2	4
23	Oral Anticoagulation and Cardiovascular Outcomes in Patients With Atrial Fibrillation and End-Stage Renal Disease. Journal of the American College of Cardiology, 2020, 75, 1299-1308.	2.8	42
24	Periprocedural Risk and Survival Associated With Implantable Cardioverter-Defibrillator Placement in Older Patients With Advanced Heart Failure. JAMA Cardiology, 2020, 5, 643-651.	6.1	7
25	Author's Reply Hemodynamic collapse following protamine sulfate: The impact of acute pulmonary vasoconstriction. Heart Rhythm Case Reports, 2020, 6, 547.	0.4	0
26	One-year mortality after implantable cardioverter-defibrillator placement within the Veterans Affairs Health System. European Journal of Heart Failure, 2020, 22, 859-867.	7.1	19
27	Preprocedural computed tomography before cardiac implanted electronic device lead extraction: Indication, technique, and approach to interpretation. Journal of Cardiovascular Electrophysiology, 2020, 31, 723-732.	1.7	5
28	Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter. American Heart Journal, 2020, 222, 26-29.	2.7	11
29	Predictors of Cardiac Perforation With Catheter Ablation of Atrial Fibrillation. JACC: Clinical Electrophysiology, 2020, 6, 636-645.	3.2	36
30	Implantable cardioverter-defibrillator lead revision following left ventricular assist device implantation. Journal of Cardiovascular Electrophysiology, 2020, 31, 1509-1518.	1.7	3
31	Subcutaneous implantable cardioverter-defibrillator troubleshooting in patients with a left ventricular assist device: A case series and systematic review. Heart Rhythm, 2020, 17, 1536-1544.	0.7	21
32	Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. JAMA Cardiology, 2019, 4, 756.	6.1	10
33	Predicting atrial fibrillation recurrence after ablation in patients with heart failure: Validity of the APPLE and CAAPAF risk scoring systems. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1440-1447.	1.2	11
34	Continuous anticoagulation with catheter ablation: answers and questions. European Heart Journal, 2019, 40, 3022-3025.	2.2	2
35	Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. Clinical Cardiology, 2019, 42, 568-571.	1.8	80
36	Stroke prevention in atrial fibrillation: Closing the gap. American Heart Journal, 2019, 210, 29-38.	2.7	8

#	ARTICLE	IF	CITATIONS
37	Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea: A Pooled Cohort Analysis. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 1747-1755.	2.6	20
38	Dofetilide dose reductions and discontinuations in women compared with men. <i>Heart Rhythm</i> , 2018, 15, 478-484.	0.7	28
39	The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients. <i>American Heart Journal</i> , 2018, 201, 17-24.	2.7	6
40	Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2018, 20, 525-532.	7.1	29
41	Traumatic injury: another unjustified reason to stop oral anticoagulation for atrial fibrillation. <i>European Heart Journal</i> , 2018, 39, 1706-1708.	2.2	1
42	Atrial fibrillation ablation alone or atrial fibrillation ablation plus an antiarrhythmic drug?. <i>European Heart Journal</i> , 2018, 39, 1438-1441.	2.2	9
43	Left Atrial Appendage Electrical Isolation for Treatment of Recurrent Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 112-120.	3.2	31
44	Knowledge and Insights Vested in Us by the VEST. <i>Circulation</i> , 2018, 138, 2735-2737.	1.6	2
45	Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. <i>Heart</i> , 2018, 104, 1850-1858.	2.9	23
46	Risk of atrioesophageal fistula formation with contact force-sensing catheters. <i>Heart Rhythm</i> , 2017, 14, 1328-1333.	0.7	91
47	New Treatment Options Fail to Close the Anticoagulation Gap in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2485-2487.	2.8	8
48	Temporal Trends in and Factors Associated With Use of Single Versus Dual-Coil Implantable Cardioverter-Defibrillator Leads. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 612-619.	3.2	10
49	When Less Is Not More. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2791-2793.	2.8	8
50	Chocolate and prevention of atrial fibrillation: what is bad for the pancreas might be good for the atria?. <i>Heart</i> , 2017, 103, 1141-1142.	2.9	4
51	Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. <i>American Journal of Cardiology</i> , 2017, 119, 1401-1406.	1.6	2
52	Outcomes Associated With Extraction Versus Capping and Abandoning Pacing and Defibrillator Leads. <i>Circulation</i> , 2017, 136, 1387-1395.	1.6	58
53	Regional differences in presentation and antithrombotic treatment of patients with atrial fibrillation: Baseline characteristics from a clustered randomized trial to IMPROVE treatment with AntiCoagulanTs in patients with atrial fibrillation (IMPACT-AF). <i>American Heart Journal</i> , 2017, 192, 38-47.	2.7	5
54	Implantable Cardioverter-Defibrillators in Patients With Left Ventricular Assist Devices. <i>JACC: Heart Failure</i> , 2017, 5, 927-929.	4.1	1

#	ARTICLE	IF	CITATIONS
55	Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy. <i>Circulation</i> , 2017, 136, 1781-1783.	1.6	6
56	Cardioversion and subsequent quality of life and natural history of atrial fibrillation. <i>American Heart Journal</i> , 2017, 185, 59-66.	2.7	18
57	Reassessment of Cardiac Function and Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Myocardial Infarction. <i>Circulation</i> , 2017, 135, 38-47.	1.6	16
58	A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. <i>Lancet</i> , 2017, 390, 1737-1746.	13.7	154
59	A clustered randomized trial to IMPROVE treatment with AnticoagulantS in patients with Atrial Fibrillation (IMPACT-AF): design and rationale. <i>American Heart Journal</i> , 2016, 176, 107-113.	2.7	8
60	Catheter ablation of ventricular tachycardia: Lessons learned from past clinical trials and implications for future clinical trials. <i>Heart Rhythm</i> , 2016, 13, 1748-1754.	0.7	28
61	Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. <i>Circulation</i> , 2016, 134, 1122-1124.	1.6	6
62	Stability of International Normalized Ratios in Patients Taking Long-term Warfarin Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 661.	7.4	33
63	Cost-Effectiveness of Left Atrial Appendage Occlusion. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	4.8	2
64	Ranolazine reduces atrial fibrillatory wave frequency. <i>Europace</i> , 2016, 19, euw200.	1.7	7
65	Challenges in atrial fibrillation beyond stroke prevention: keeping patients out of the hospital. <i>Europace</i> , 2016, 18, 1117-1118.	1.7	0
66	High-degree atrioventricular block, asystole, and electro-mechanical dissociation complicating non-ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016, 171, 25-32.	2.7	11
67	Assessing generalizability of trial results in general practice. <i>European Heart Journal</i> , 2016, 37, 1154-1157.	2.2	11
68	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	3.7	127
69	Catheter ablation for ventricular tachycardia (VT) in patients with ischemic heart disease: a systematic review and a meta-analysis of randomized controlled trials. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2016, 45, 111-117.	1.3	18
70	Practical advice on safe and effective use of non-vitamin K antagonist oral anticoagulants. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 146-147.	3.0	1
71	Use of Implantable Cardioverter-Defibrillators Among Medicare Patients—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 1874.	7.4	4
72	Blending Quality Improvement and Research Methods for Implementation Science, Part II. <i>AACN Advanced Critical Care</i> , 2015, 26, 366-371.	1.1	2

#	ARTICLE	IF	CITATIONS
73	Cable externalization and electrical failure of the Riata family of implantable cardioverter-defibrillator leads: A systematic review and meta-analysis. <i>Heart Rhythm</i> , 2015, 12, 1233-1240.	0.7	35
74	Calcified Pipes. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, .	2.6	0
75	Implantable Cardioverter-Defibrillator Use Among Medicare Patients With Low Ejection Fraction After Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2433.	7.4	50
76	Should patients on vitamin K antagonists be treated differently?. <i>European Heart Journal</i> , 2015, 36, 1431-1433.	2.2	5
77	Management of Pace-Terminated Ventricular Arrhythmias. <i>Cardiac Electrophysiology Clinics</i> , 2015, 7, 497-513.	1.7	2
78	Patientsâ€™ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. <i>American Heart Journal</i> , 2015, 170, 141-148.e1.	2.7	211
79	Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?. <i>Journal of the American Heart Association</i> , 2015, 4, e001573.	3.7	20
80	Optimal Management of Riata Leads with No Known Electrical Abnormalities or Externalization: A Decision Analysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 184-191.	1.7	6
81	Blending Quality Improvement and Research Methods for Implementation Science, Part II: Analysis of the Quality of Implementation. <i>AACN Advanced Critical Care</i> , 2015, 26, 366-371.	1.1	1
82	Novel mechanism of premature battery failure due to lithium cluster formation in implantable cardioverter-defibrillators. <i>Heart Rhythm</i> , 2014, 11, 2190-2195.	0.7	19
83	Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: A systematic review. <i>International Journal of Cardiology</i> , 2014, 177, 990-994.	1.7	14
84	Periprocedural imaging and outcomes after catheter ablation of atrial fibrillation. <i>Heart</i> , 2014, 100, 1871-1877.	2.9	16
85	Cost Analysis of Periprocedural Imaging in Patients Undergoing Catheter Ablation for Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2014, 114, 266-271.	1.6	5
86	Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 163-174.	2.1	18
87	Infarct healing is a dynamic process following acute myocardial infarction. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2012, 14, 62.	3.3	51
88	Atrial Fibrillation Complicating Acute Coronary Syndromes. <i>Journal of Atrial Fibrillation</i> , 2012, 5, 611.	0.5	3
89	Effect of Amiodarone-Induced Hyperthyroidism on Left Ventricular Outflow Obstruction After Septal Myectomy for Hypertrophic Cardiomyopathy. <i>American Journal of Cardiology</i> , 2010, 106, 1670-1672.	1.6	1